Sunday 18 October 2026
Export NVAX’s income statement to Excel — free account
Novavax, Inc.
NVAX Healthcare Biotechnology
Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 148.5%, free cash flow grew 43.0% and total debt rose 31.5%, each against the same quarter a year earlier.
11.26
1.56
−12.17%
Follow NVAX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
4.09 | 2.45 | 0.00 | 0.00 |
P/S ratio |
1.32 | 0.97 | 2.23 | 3.75 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
13.06 | (27.58) | (40.99) | (21.29) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.83 | 0.52 | 1.39 | 2.72 | |
EV/EBITDA |
2.57 | 1.23 | 0.00 | 0.00 | |
EV/Operating CF |
(2.33) | (2.41) | (9.08) | (30.46) | |
EV/FCF |
(4.56) | (2.34) | (8.43) | (25.52) | |
Quick Ratio |
1.88 | 1.85 | 2.38 | 2.23 | |
Current Ratio |
2.27 | 2.13 | 2.48 | 2.33 | |
Net Debt/EBITDA |
3.08 | (25.82) | 40.22 | 8.22 | |
Debt/Assets |
20.86% | 20.94% | 28.08% | 30.68% | |
Debt/Equity |
(1.57) | (1.93) | (2.02) | (1.54) | |
Asset Turnover |
0.74 | 0.82 | 0.51 | 0.36 | |
Operating CF/Net income |
(0.53) | (2.25) | 3.42 | 1.36 | |
Capex/Depreciation |
(0.31) | (0.44) | (0.41) | (0.19) | |
Interest Coverage |
(32.47) | 2.44 | (3.15) | (9.65) | |
Research and Development Expense of Revenue |
139.50% | 51.57% | 68.43% | 124.68% | |
Selling, General and Administrative Expense of Revenue |
44.94% | 23.19% | 20.63% | 47.03% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.11 | 0.12 | |
Share Based Compensation of Revenue |
12.14% | 5.41% | 5.54% | 14.27% | |
Graham Net Nets |
(0.26) | (0.30) | (0.25) | (0.24) | |
Graham Number |
0.00 | 0.00 | 3.28 | 6.30 | |
Earnings Yield |
24.45% | 40.77% | (6.63%) | (16.14%) | |
Free Cash Flow Yield |
(13.72%) | (23.15%) | (7.42%) | (2.84%) | |
Revenue per Share |
0.43 | 0.91 | 0.85 | 0.34 | |
Operating CF per Share |
0.66 | (0.24) | (0.20) | (0.44) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.65 | (0.26) | (0.21) | (0.45) | |
Cash per Share |
4.77 | 4.60 | 4.84 | 4.37 | |
Shareholders Equity per Share |
(0.96) | (0.79) | (0.89) | (1.16) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.96) | (0.79) | (0.89) | (1.16) | |
Free Cash Flow |
105.79 | (41.72) | (33.69) | (73.39) | |
Working Capital |
544.72 | 518.33 | 508.36 | 440.52 | |
Capital Expenditures |
(2.02) | (2.25) | (1.27) | (0.59) | |
Net Current Asset Value |
(361.97) | (325.99) | (337.11) | (375.18) | |
EV/EBIT |
2.86 | 1.30 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.01 | |
Price to Operating Income |
4.58 | 2.40 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
64.57 | 107.37 | 33.91 | 122.57 | |
Average Payables |
36.37 | 33.08 | 25.13 | 36.77 | |
Average Inventory |
11.07 | 10.15 | 10.86 | 10.12 | |
Average Assets |
1,446.19 | 1,368.47 | 1,168.08 | 1,146.06 | |
Average Common Equity |
(341.55) | (375.80) | (110.20) | (76.54) |
Columns are period end dates